Torrent Pharmaceuticals has entered into a strategic alliance with Boehringer Ingelheim India to co-market Cospiaq, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus. Empagliflozin is also indicated to reduce the risk of cardiovascular death, in adults with type 2 diabetes mellitus and established cardiovascular disease

Torrent Pharmaceuticals has entered into a strategic alliance with Boehringer Ingelheim India to co-market Cospiaq (Empagliflozin), Cospiaq MetTM (Empagliflozin+ Metformin) and Xilingio  (Empagliflozin+ Linagliptin) in India, the pharma companies informed in a joint statement on Wednesday.

Empagliflozin is useful for improving glycaemic control in adults with type-2 diabetes mellitus. Empagliflozin is also indicated to reduce the risk of cardiovascular death, in adults with type 2 diabetes mellitus and established cardiovascular disease.

Further, empagliflozin is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure, in adults with heart failure. 

As per International Diabetes Federation, India has the second largest diabetes patient base in the world with an estimated 74.2 million adults (20-79 years age group) as of 2021. This is expected to increase to almost 125 million patients by 2045. According to AWACS MAT, October 2022 data, the Indian diabetes medications market is valued at INR 16,516 crore, growing at 8.6 per cent CAGR over the last 4 years.

The market for SGLT-2 Inhibitors is valued at 1,927 Crores and the SGLT-2 Inhibitors are growing faster than the diabetes market faster at 33 per cent CAGR over the same time period. 

Aman Mehta, Director, Torrent Pharmaceuticals said, “Torrent is delighted to enter into a strategic partnership with Boehringer Ingelheim India to address the dual challenges of type-2 diabetes and heart failure (both preserved and reduced ejection fractions) in India.” 

“Our collaboration with Torrent reaffirms our commitment towards enabling improved access to innovative medicine in India. We believe that the coming together of the healthcare ecosystem is key to address unmet needs of patients," stated Vani Manja, Managing Director, Boehringer Ingelheim India.